Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Ohno

Showing results (361-370 of 400) with videos related to

Pageof 40
Sort By:
International Journal of Hematology|May 22, 1998
Pregnancy among long-term survivors of acute leukemia. A second nationwide surveyS Kawamura, R Ueda, R Ohno, et al.
Leukemia|April 18, 2002
Arsenic trioxide therapy for relapsed or refractory Japanese patients with acute promyelocytic leukemia: need for careful electrocardiogram monitoringK Ohnishi, H Yoshida, K Shigeno, et al.
Annals of Internal Medicine|December 5, 2000
Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemiaK Ohnishi, H Yoshida, K Shigeno, et al.
British Journal of Haematology|August 6, 2000
Induction therapy consisting of alternating cycles of ranimustine, vincristine, melphalan, dexamethasone and interferon alpha (ROAD-IN) and a randomized comparison of interferon alpha maintenance in multiple myeloma: a co-operative study in JapanM Wada, H Mizoguchi, S I Kuriya, et al.
Leukemia|January 17, 2003
Possible dominant-negative mutation of the SHIP gene in acute myeloid leukemiaJ-M Luo, H Yoshida, S Komura, et al.
Leukemia|May 1, 1997
Morphological subtyping of acute myeloid leukemia with maturation (AML-M2): homogeneous pink-colored cytoplasm of mature neutrophils is most characteristic of AML-M2 with t(8;21)H Nakamura, K Kuriyama, N Sadamori, et al.
International Journal of Hematology|January 22, 2000
Infectious complications during remission induction therapy in 577 patients with acute myeloid leukemia in the Japan Adult Leukemia Study Group studies between 1987 and 1991M Yoshida, K Tsubaki, T Kobayashi, et al.
International Journal of Hematology|April 4, 2000
Efficacy of a new formulation of lenograstim (recombinant glycosylated human granulocyte colony-stimulating factor) containing gelatin for the treatment of neutropenia after consolidation chemotherapy in patients with acute myeloid leukemiaA Takeshita, H Saito, K Toyama, et al.
Japanese Journal of Cancer Research : Gann|June 30, 2000
Spicamycin and KRN5500 induce apoptosis in myeloid and lymphoid cell lines with down-regulation of bcl-2 expression and modulation of promyelocytic leukemia proteinW J Zhang, K Ohnishi, H Yoshida, et al.
International Journal of Hematology|October 20, 2000
Combination chemotherapy with risk factor-adjusted dose attenuation for high-risk myelodysplastic syndrome and resulting leukemia in the multicenter study of the Japan Adult Leukemia Study Group (JALSG): results of an interim analysisT Okamoto, A Kanamaru, C Shimazaki, et al.
Pageof 40

Showing results (361-370 of 400) with videos related to

Sort By:
Pageof 40
International Journal of Hematology|May 22, 1998
Pregnancy among long-term survivors of acute leukemia. A second nationwide surveyS Kawamura, R Ueda, R Ohno, et al.
Leukemia|April 18, 2002
Arsenic trioxide therapy for relapsed or refractory Japanese patients with acute promyelocytic leukemia: need for careful electrocardiogram monitoringK Ohnishi, H Yoshida, K Shigeno, et al.
Annals of Internal Medicine|December 5, 2000
Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemiaK Ohnishi, H Yoshida, K Shigeno, et al.
British Journal of Haematology|August 6, 2000
Induction therapy consisting of alternating cycles of ranimustine, vincristine, melphalan, dexamethasone and interferon alpha (ROAD-IN) and a randomized comparison of interferon alpha maintenance in multiple myeloma: a co-operative study in JapanM Wada, H Mizoguchi, S I Kuriya, et al.
Leukemia|January 17, 2003
Possible dominant-negative mutation of the SHIP gene in acute myeloid leukemiaJ-M Luo, H Yoshida, S Komura, et al.
Leukemia|May 1, 1997
Morphological subtyping of acute myeloid leukemia with maturation (AML-M2): homogeneous pink-colored cytoplasm of mature neutrophils is most characteristic of AML-M2 with t(8;21)H Nakamura, K Kuriyama, N Sadamori, et al.
International Journal of Hematology|January 22, 2000
Infectious complications during remission induction therapy in 577 patients with acute myeloid leukemia in the Japan Adult Leukemia Study Group studies between 1987 and 1991M Yoshida, K Tsubaki, T Kobayashi, et al.
International Journal of Hematology|April 4, 2000
Efficacy of a new formulation of lenograstim (recombinant glycosylated human granulocyte colony-stimulating factor) containing gelatin for the treatment of neutropenia after consolidation chemotherapy in patients with acute myeloid leukemiaA Takeshita, H Saito, K Toyama, et al.
Japanese Journal of Cancer Research : Gann|June 30, 2000
Spicamycin and KRN5500 induce apoptosis in myeloid and lymphoid cell lines with down-regulation of bcl-2 expression and modulation of promyelocytic leukemia proteinW J Zhang, K Ohnishi, H Yoshida, et al.
International Journal of Hematology|October 20, 2000
Combination chemotherapy with risk factor-adjusted dose attenuation for high-risk myelodysplastic syndrome and resulting leukemia in the multicenter study of the Japan Adult Leukemia Study Group (JALSG): results of an interim analysisT Okamoto, A Kanamaru, C Shimazaki, et al.
Pageof 40